Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 30, 2008

View Archived Issues

Santen patents novel HDAC inhibitors for glaucoma

Recent patents divulge novel analgesic agents

Novel agents for treating thrombosis disclosed in recent Wyeth patent

Clinical Data and Avalon enter into definitive merger agreement

Broad-spectrum antifungal activity seen with AN-2718 in vitro

Studies detail effects of prucalopride in chronic constipation, intestinal pseudo-obstruction

CombinatoRx provides data from phase IIb osteoarthritis study with Synavive

Chelsea completes enrollment in phase II clinical trial of CH-1504 in RA

Nycomed reports encouraging results from four phase III trials of Daxas in COPD

Provectus successfully completes phase I clinical trial of PV-10 in recurrent breast cancer

BioWa licenses Potelligent to KaloBios

Wakunaga identifies novel fluoroquinolone with activity against resistant respiratory bacteria

Cipher provides update on CIP-Tramadol ER regulatory filing

EMD Serono and Theratechnologies collaborate for tesamorelin in the U.S.

HealthLinx launches OvPlex ovarian cancer screening test in Australia

BioMimetic reports clinical results using Augment Injectable Bone Graft

Northfield Laboratories submits BLA to FDA for PolyHeme red cell substitute

Bristol-Myers Squibb presents studies of BMS-582949 in humans

Oral formulation of 17-AAG metabolite IPI-493 displays potency, in vivo activity

Phenomix initiates treatment in phase Ia clinical trial of protease inhibitor PHX-1766 in HCV

Phase I and other data on HDAC inhibitor SB-939 presented

Applied Biosystems stockholders approve proposed merger with Invitrogen

South Africa Medicines Control Council discontinues registration of Biopure's Hemopure

Anadys initiates dosing in phase Ib clinical trial of ANA-598 in HCV infection

FDA approves sanofi-aventis' Apidra insulin for diabetic children aged 4 years and older

ImClone Systems launches monoclonal antibody Erbitux in Canada for mCRC

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...